Clin2
NCT06639464Possibly a fitRecruiting

Semaglutide to help with opioid recovery

Opioid Use Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests if semaglutide, a medicine sometimes used for weight management, can help people recovering from opioid use disorder stay on track. It is for adults who have already started buprenorphine treatment and are ready to take part in a research study.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
46 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older and speak English.
  • You must have a diagnosis of severe opioid use disorder and have started buprenorphine treatment within the past 60 days.
  • You must be on a stable dose of at least 16 mg of buprenorphine for 30 days before joining.
  • You must be willing to continue buprenorphine during the study and let the study team check your prescription.
  • You must not have certain other medical conditions, such as diabetes, heart disease, or a history of eating disorders.
  • Your body mass index (BMI) must be 25 or higher.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06548490Recruiting· Phase 2
Semaglutide for Opioid Use Disorder

This study tests whether a once-weekly injection of semaglutide (a GLP-1 receptor agonist) can reduce opioid use in people who are already on buprenorphine or methadone but still using opioids. It lasts about 19 weeks.

Baltimore, Maryland
NCT07223983Recruiting· Phase 1
Semaglutide for alcohol use disorder after weight loss surgery

This trial tests if a once-weekly diabetes medication (semaglutide) can help people with alcohol use disorder who have had gastric bypass or sleeve gastrectomy in the past 7 years. It may reduce alcohol cravings or drinking.

New Haven, Connecticut
NCT07772960Not yet recruiting· Phase 1
Semaglutide for alcohol use and weight loss

This study tests whether semaglutide, a medication that helps with weight loss, can also reduce alcohol cravings and drinking in people with alcohol use disorder. It may help you drink less and lose weight.

New Haven, Connecticut
NCT07509112Not yet recruiting· Phase 2
Semaglutide for treating methamphetamine use disorder

This trial tests if semaglutide, a medication that affects appetite and cravings, can help people reduce or stop using methamphetamine. It may be a new option for those struggling with moderate to severe methamphetamine use disorder.

Darlinghurst, New South Wales
NCT07523633Recruiting· Phase 2
Semaglutide to help reduce cannabis use disorder

This trial tests whether a medication called semaglutide (used for weight management) can help adults with cannabis use disorder cut down or stop using cannabis. Researchers want to see if it reduces cravings and use while also monitoring overall health.

Frederiksberg
NCT06825793Not yet recruiting
Semaglutide for weight loss in obesity

This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.

Hear when a new Opioid Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.